News

All news CSR Events General PERSONAL CARE Press release Products & Technologies Protéus

CELLforCURE launches a process to find a buyer for its Les Ulis site

CELLforCURE, a subsidiary of the SEQENS Group, has informed its employee representatives of its decision to look for a potential buyer for its site in Les Ulis (Essonne). CELLforCURE specializes in the development and the contract manufacturing of Cell & Gene therapies.

European Industry Summit: Pierre Luzeau, CEO of Seqens joins 73 industry leaders to call for a European Industrial Deal

Seqens and KK India petroleum specialties PVT LTD announce new partnership for lubricant additives in India

Seqens partners with Pleryon to develop and manufacture an innovative GMP Polymer to treat osteoarthritis

Seqens confirms the acquisition of CELLforCURE

SEQENS Makes Multi-Million-Dollar Investment in U.S. R&D Laboratory

SK Capital becomes the new majority shareholder of Seqens – Q&A

SEQENS unveils its new pharmaceutical quality control laboratory in the presence of Jean Castex, French Prime Minister.

Eurazeo announces that it has entered into exclusive discussions to sell its stake in SEQENS

Labcom HitCat Inauguration in partnership with the CNRS

France Relance program: SEQENS new paracetamol production unit

Essential molecules’ production in France: our investment plan

Seqens’ commitment to reducing its carbon footprint

1 2 3